Effects of Nasal-spraying LiveSpo Navax in Treatment of Influenza Virus in Children
Status:
Completed
Trial end date:
2022-04-22
Target enrollment:
Participant gender:
Summary
Acute Respiratory Tract Infections (ARTIs) in children are common diseases, with influenza
virus types A and B is one of the main causes of serious symptoms in young children. Although
an influenza vaccine is available, influenza vaccination requires annual injections, which
made it difficult for young children to get effectively immunized. Moreover, antiviral
nucleotide drugs including Tamiflu (oseltamivir) are unsafe for young children and are
recommended only for high-risk patients. Probiotics have emerged as promising safe candidates
for supportive treatment of ARTIs and reduction of antibiotic dependence in recent years.
Here, we propose that direct spraying of probiotics into the nose can be a fast and effective
symptomatic treatment for ARTIs due to influenza virus.
The aim of the study about to evaluate the effectiveness of nasal-spraying probiotics
containing spores of two bacterial strains, Bacillus subtilis and Bacillus clausii in
preventing and supporting the treatment of children having acute respiratory symptoms due to
influenza infection.
Study Population: sample size is 70. Description of Sites: the study is carried out at
Vietnam National Children's Hospital.
Description of Study Intervention: totally 70 eligible patients are divided randomly into 2
groups (n = 35/group each): Patients in Control group received the routine treatment and
three times per day 0.9% NaCl physiological saline while the patients in the Navax group
received three times per day LiveSpo Navax in addition to the same standard of care
treatment. The standard treatment regimen is 2-5 days but can be extended further depending
on the severity of the patient's respiratory failure.
Study duration: 15 months